Stockreport

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]

IN8bio, Inc.  (INAB) 
PDF potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential to achieve deep B cell depletion with an improve [Read more]